🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Baxter sells BioPharma to Advent and Warburg for $4.25 billion in cash

Published 05/08/2023, 10:09 AM
Updated 05/08/2023, 10:18 AM
© Reuters.  Baxter (BAX) sells BioPharma to Advent and Warburg for $4.25 billion in cash
BAX
-

Baxter (NYSE:BAX) announced today a deal to divest its BioPharma Solutions business to private equity firms Advent International and Warburg Pincus in a deal worth $4.25 billion in cash.

The transaction is expected to close in the second half of 2023. Baxter said it intends to use the generated proceeds to reduce its debt.

“Today represents an important step in Baxter’s ongoing transformation journey as we continue to execute against our strategic priorities, enhance our focus and create additional value for all our stakeholders,” said José (Joe) E. Almeida, Chairman, President and Chief Executive Officer at Baxter.

The medtech company sees the deal resulting in dilution of approximately $0.10 per share to the company’s earnings. BPS is seen generating about $600 million in 2023 sales, Baxter said.

“BPS is a premier asset at the forefront of the biopharma industry, and one we’ve been closely following for a number of years,” said John Maldonado, a Managing Partner at Advent.

Baxter stock is moving higher on Monday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.